10 Regulus Therapeutics Analyst Ratings, Earnings, Dividends and Insider Trades | $RGLS | NASDAQ:RGLS | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Regulus Therapeutics Company Profile (NASDAQ:RGLS) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Regulus Therapeutics (NASDAQ:RGLS) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)Consensus Rating:Buy (Score: 2.83)Consensus Price Target: $15.75 (50.43% upside) Analysts' Ratings History for Regulus Therapeutics (NASDAQ:RGLS) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare2/28/2014Needham & CompanyBoost Price Target$14.00View 2/7/2014WedbushBoost Price Target$17.00 -> $19.00View 1/20/2014TheStreetUpgradeSell -> HoldView 11/14/2013Cowen and CompanyReiterated RatingOutperformView 10/30/2013FBR & Co.Initiated CoverageOutperformView 10/30/2013FBR Capital MarketsInitiated CoverageOutperformView 8/19/2013WedbushBoost Price TargetOutperform$10.00 -> $17.00View 8/14/2013Lazard Capital MarketsBoost Price TargetBuy$14.00 -> $15.00View 8/14/2013BMO Capital MarketsReiterated RatingOutperform$10.00 -> $15.00View 8/14/2013Needham & CompanyBoost Price TargetBuy$8.00 -> $12.00View 5/15/2013Needham & CompanyReiterated RatingBuyView 11/29/2012WedbushInitiated CoverageOutperform$10.00View 11/5/2012Needham & CompanyInitiated CoverageBuy$8.00View 11/1/2012Lazard Ltd.Initiated CoverageBuy$14.00View 10/31/2012BMO Capital MarketsInitiated CoverageOutperformView 10/31/2012Cowen and CompanyInitiated CoverageOutperformView (Data available from 3/12/2012 forward) Earnings History for Regulus Therapeutics (NASDAQ:RGLS)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/27/2014($0.13)($0.11)ViewN/AView 8/13/20132Q13($0.14)($0.20)$3.44 million$4.80 millionViewN/AView 2/20/2013Q412($0.08)($0.22)$3.50 million$3.24 millionViewN/AView 11/19/2012Q312$0.00($15.98)$3.81 million$2.80 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Regulus Therapeutics (NASDAQ:RGLS)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Regulus Therapeutics (NASDAQ:RGLS)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/4/2014Sanofimajor shareholderBuy1,303,780$7.67$9,999,992.60View 1/21/2014Neil GibsonInsiderSell4,421$8.09$35,765.89View 1/17/2014Neil GibsonInsiderSell4,479$8.15$36,503.85View 1/16/2014Neil GibsonInsiderSell1,100$8.03$8,833.00View 1/2/2014Kleanthis XanthopoulosCEOSell3,505$7.25$25,411.25View 10/10/2012Stanley T CrookeDirectorBuy750,000$4.00$3,000,000.00View (Data available from 1/1/2013 forward) About Regulus Therapeutics Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing first-in-class drugs that target microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid, (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses microRNA product platform to develop chemically modified, single-stranded oligonucleotides which it calls anti-miRs. It uses these anti-miRs to modulate microRNAs and by doing so return diseased cells to their healthy state. In August 2012, the Company formed a strategic alliance with AstraZeneca to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases and oncology. Headlines: (3/11) Focus on Regulus' Pipeline (2/26) Regulus to Present at Cowen and Company 34th Annual Healthcare Conference (2/20) Regulus Announces Timing for Fourth Quarter and Year-End 2013 Financial Results Webcast and Conference Call (2/20) Pipeline Progress at Regulus (3/5) Regulus Commences Dosing RG-101 in Healthy Volunteers in Phase I Study (3/5) Press Release (2/27) Regulus Provides Strategic Update and Reports Fourth Quarter and Year-End 2013 Financial Results and Recent Highlights (2/19) Regulus Advances Orphan Disease Portfolio with Nomination of RG-012 as Clinical Development Candidate for the ... Industry, Sector and Symbol: Sector: Healthcare Industry: Biotechnology Sub-Industry: Biotechnology Exchange: NASDAQ Symbol: RGLS CUSIP: 75915K10 Key Metrics: Previous Close: $10.4550 Day Moving Average: $9.7323200 Day Moving Average: $8.246 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $452.0MCurrent Quarter EPS Consensus Estimate: $-0.58 EPS Additional Links: View RGLS on Google FinanceView RGLS on Yahoo FinanceView RGLS's Company Profile on ReutersSearch for Regulus Therapeutics Inc. on Google Regulus Therapeutics (NASDAQ:RGLS) Chart for Wednesday, March, 12, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.